您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Tandutinib(MLN518)HCl
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tandutinib(MLN518)HCl
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tandutinib(MLN518)HCl图片
规格:98%
分子量:599.16
包装与价格:
包装价格(元)
100mg电议
200mg电议
500mg电议

产品介绍
FLT3 inhibitor,potent and selective
货号:ajcx11128
CAS:N/A
分子式:C31H43ClN6O4
分子量:599.16
溶解度:≥ 59.9mg/mL in DMSO
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Tandutinib, also known as MLN518 or CT53518, is a potent antagonist for FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit [1].

FLT3 is expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. High levels of wild-type FLT3 have been observed in some AML patients and may be associated with worse prognosis.

Tandutinib potently inhibited the activity of FLT3, PDGFR, and c-Kit with the IC50 value of ~200 nM. Tandutinib showed no significant effects on other tyrosine or serine/threonine kinases. In Ba/F3 cells expressing different FLT3-ITD mutants, Tandutinib inhibited IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC50 of 10–100 nM. In human FLT3-ITD-positive AML cell lines, Tandutinib induced apoptosis and inhibited FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways [1]. Tandutinib inhibited phosphorylation of c-Kit, Akt, mTOR, and p70S6 kinase. Tandutinib significantly inhibited the proliferation and colony formation ability of colon cancer cell lines [2]. Tandutinib decreased the expression level of COX-2, VEGF, and interleukin-8. Intraperitoneal administration of tandutinib significantly suppressed growth of colon cancer tumor xenografts. Tandutinib inhibited the expression of cancer-promoting genes COX-2 and VEGF and suppressed the activation of Akt/mTOR signaling proteins in the xenograft tissues [2].

参考文献:
[1] Kelly L M, Yu J C, Boulton C L, et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)[J]. Cancer cell, 2002, 1(5): 421-432.
[2] Ponnurangam S, Standing D, Rangarajan P, et al.  Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth[J]. Molecular cancer therapeutics, 2013, 12(5): 598-609.